Title:
HUMANIZED ANTI-CD19 ANTIBODY AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2017/015783
Kind Code:
A1
Abstract:
Provided is a humanized anti-CD19 antibody comprising a heavy chain variable region sequence showed as SEQ ID NO: 27 and a light chain variable region sequence showed as SEQ ID NO: 34, SEQ ID NO: 35 or SEQ ID NO: 36, and methods of using such antibody for treating CD19 related disorder or disease.
Inventors:
WU ZHAO (CN)
LIU ZHIGANG (CN)
LIU ZHIGANG (CN)
Application Number:
PCT/CN2015/084991
Publication Date:
February 02, 2017
Filing Date:
July 24, 2015
Export Citation:
Assignee:
SHANGHAI SIDANSAI BIOTECHNOLOGY CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61P35/02; A61P37/00; C07K16/46; C12N5/10; C12N15/13; C12N15/63
Domestic Patent References:
| WO2010095031A2 | 2010-08-26 | |||
| WO2005012493A2 | 2005-02-10 | |||
| WO2010102276A2 | 2010-09-10 | |||
| WO2013138244A2 | 2013-09-19 |
Other References:
KUGLER M ET AL.: "Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD 19 by designed point mutations and CDR-grafting onto a human framework", PROTEIN ENG DES SEL, vol. 22, no. 3, 31 March 2009 (2009-03-31), pages 135 - 147, XP002575212
Attorney, Agent or Firm:
BEIJING JWT INTELLECTUAL PROPERTY CO., LTD. (CN)
Download PDF:
Previous Patent: NOVEL AXIAL PISTON PUMP
Next Patent: ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR
Next Patent: ORBIT AZINE-FUMARATE, HYDRATE, CRYSTAL FORM AND PREPARATION METHOD THEREFOR